FLT3 and myelodysplastic syndrome: Analysis of 278 MDS patients with low- or intermediate-1-risk MDS revealed that the detection of a RAS or FLT3-ITD mutation is associated with a particularly high risk of progression to AML-MRC with very poor response to treatment with hypomethylating agents [11].